CDMO Selection for Biotech: The Criteria That Actually Predict Success
Written byNeta Kela, PhDFounder & Managing PartnerSelecting a contract development and manufacturing organisation is usually run as a procurement exercise: scope, quote, capacity, timeline, sign. Then, eighteen months later, it turns out to have been a regulatory decision. The comparability position, the analytical package, the impurity profile, and the change control history in your submission all belong to that choice.
Why the decision is regulatory, not commercial
Whatever your CDMO does becomes your data. Their process is the process you file. Their methods are the methods you defend. Their deviations appear in your submission. If they cannot support a change eighteen months from now, you inherit a comparability exercise you did not plan.
That reframing changes what you evaluate.
Criteria that predict success
Relevant modality experience, at your scale. A facility that runs commercial monoclonal antibodies is not automatically a fit for a viral vector or an ADC at 50 litre scale. Ask for programs of the same modality at a similar phase, and what happened to them.
Regulatory track record. How many filings has this site supported? Has it been inspected, by which agencies, and what was the outcome? A site with no submission history is not disqualifying, but it means your program is the learning curve.
Analytical capability in-house. Analytical development and quality control are where early programs most often stall. A CDMO that outsources its analytics adds a handoff at exactly the point where you need speed and traceability.
Technology transfer discipline. Ask to see their transfer protocol template and their record of transfers completed on schedule. Transfer failure is the most common source of unplanned delay.
Change control and comparability posture. Ask directly: when we change scale or a raw material, how do you support comparability? A vague answer here predicts an expensive problem later.
Capacity that is real and reserved. Confirmed slots, in writing, with what happens if they slip. Verbal capacity assurances are not capacity.
Attention you will actually receive. Small programs at large CDMOs are routinely deprioritised. Ask who your project manager is, how many programs they carry, and what escalation looks like.
Questions to ask before signing
- Which programs of our modality and phase have you run in the past three years, and can we speak to one of those sponsors?
- What was the outcome of your most recent regulatory inspection?
- Which analytical methods will you develop, and which will you use ours or a third party's?
- What is your on-time delivery record for technology transfers in the past two years?
- Who owns the process and the analytical methods, and what happens to that ownership if we leave?
- How is comparability handled when the process changes, and who pays for it?
- What deviations occurred in the last three batches of a comparable product, and how were they closed?
Contract terms teams later regret omitting
- Ownership of process and analytical know-how, stated explicitly.
- Exit and transfer rights, including the documentation package you receive on leaving.
- Right to audit, and to be present for key operations.
- Defined data package deliverables, not just batch deliverables. Submissions need the data, not the material.
- Named capacity slots with remedies for slippage.
- Change notification obligations before, not after, the change.
The single-source question
Sole sourcing early is normal and often correct, because dual sourcing before you know your process is expensive. The mistake is not sole sourcing, it is sole sourcing without a documented view of what a transfer would take. Know the answer before you need it.
The takeaway
Evaluate a CDMO on the evidence it will help you generate and defend, not on the quote. The cheapest CDMO in a bid comparison is rarely the cheapest program.
Related reading: 5 CMC strategy mistakes that delay IND filings.
If you want senior support running a CDMO selection or fixing one that is not working, see CMC strategy and manufacturing advisory or email Info@PreciseXMed.com.
Frequently Asked Questions
How PXM Helps With This
CMC Strategy & Manufacturing Readiness
CMC roadmaps, CDMO selection, comparability strategy, and CMC submissions.
FDA Regulatory Readiness & Submission Support
Pathway strategy, FDA meeting preparation, submissions, and agency responses.
Biotech Readiness Assessment
A 10 minute diagnostic of your regulatory, CMC, and partnering readiness.
Related
Part of FDA & CMC Readiness. Start from the pillar: Operate practice, FDA Regulatory Readiness, CMC & Manufacturing, FDA Expedited Pathways, EU Regulatory Pathways
What a Clinical Overview Must Contain for an EU Hybrid Application
What the Clinical Overview (Module 2.5) must cover in an EU hybrid application under Article 10(3), how to justify differences from the reference product, and where assessors push back.
Well-Established Use Applications: Building a Bibliographic Clinical Overview That Holds Up
How to build the Clinical Overview for an EU well-established use application under Article 10a: the ten-year test, literature selection, and how to bridge your product to the published evidence.
How to Choose an Independent Clinical Expert for Your EU Dossier
What Article 12 of Directive 2001/83/EC requires from the Clinical and Nonclinical Expert, what to look for when you appoint one, and the questions to ask before they sign.
Get notified when we publish new funding and regulatory guides
Practical guidance on FDA and EMA strategy, CMC readiness, and non-dilutive funding — sent only when there is something worth reading.